Gene Therapy ETX101 Cuts Dravet Seizures 76% — and Tracks Toward Neurotypical Development

Encoded Therapeutics announced Monday that its experimental gene therapy ETX101 cut seizure frequency by a median of 76 percent in children with Dravet syndrome at dose level 3, with the effect holding through 52 weeks of follow-up — a durability signal that matters enormously in a disease where existing drugs often fail within months. The more disruptive finding, buried beneath the seizure headline, is a measurable divergence in neurodevelopmental trajectories: treated children tracked toward neurotypical development curves, while an untreated natural history cohort continued to stall. That combination — durable seizure control plus developmental rescue — has not been demonstrated before in this population, and it is the reason the data, presented at the 2026 American Society of Gene and Cell Therapy (ASGCT) Presidential Symposium, drew immediate attention from researchers and patient advocates alike.

What the Research Found

The POLARIS Phase I/II trial enrolled children between six months and seven years of age with SCN1A+ Dravet syndrome — meaning patients with confirmed loss-of-function variants in the SCN1A gene. At dose level 3, children experienced a median seizure reduction of approximately 76 percent, and that reduction persisted through 52 weeks of observation. The response was dose-dependent: higher dose levels correlated with greater seizure reduction, and early data from the top dose level are being watched closely.

Beyond seizure frequency, Encoded Therapeutics reported gains on the Vineland Adaptive Behavior Scales — a caregiver-reported instrument that measures communication, motor function, and adaptive behavior — in children who reached one year of follow-up. These are domains that existing Dravet therapies rarely move. The comparison benchmark is the ENVISION natural history study, which documented the developmental stagnation typical of untreated children with Dravet syndrome. Children treated with ETX101 showed trajectories diverging from the ENVISION pattern and trending toward neurotypical development over the first year post-treatment.

The neurodevelopmental signal was strongest in the youngest patients. Children treated before age two showed the earliest and most sustained divergence from the ENVISION stagnation pattern — a subgroup finding with significant clinical implications, given that the first two years of life represent a critical window for synaptic pruning and cognitive scaffolding.

One finding added a layer of mechanistic complexity: patients at the top dose level who did not receive sirolimus — an mTOR inhibitor (a drug that suppresses the immune system by blocking a cellular growth-signaling pathway) used as an immunosuppressant in some trial participants — showed stronger responses than those who did receive it. This is consistent with preclinical data suggesting sirolimus dampens ETX101 protein expression, and raises the possibility that the therapy's ceiling has not yet been observed.

How the Science Works

Dravet syndrome is caused by loss-of-function variants in the SCN1A gene, located on chromosome 2 and encoding the Nav1.1 sodium channel protein. When SCN1A function is reduced, inhibitory interneurons — the neurons responsible for calming overactive brain circuits — cannot fire reliably. The result is a runaway excitation loop that manifests as prolonged, treatment-resistant seizures. Onset typically occurs in infancy, often triggered by fever or elevated body temperature.

ETX101 is not a gene replacement or gene-editing therapy. It is an AAV9-based gene regulation therapy: it uses an adeno-associated virus serotype 9 (a modified, non-replicating viral shell commonly used in gene therapy as a delivery vehicle) to carry an engineered transcription factor — a protein that turns genes on — into inhibitory interneurons. Once inside those cells, the transcription factor increases SCN1A expression, partially restoring Nav1.1 channel function without altering the underlying DNA sequence.

Delivery is intracerebroventricular (ICV): a single dose is injected directly into the brain's ventricular system, the fluid-filled cavities that communicate throughout the central nervous system. ICV delivery bypasses the blood-brain barrier, which AAV9 cannot efficiently cross in adults, and concentrates the therapy where it is needed. The administration is a one-time procedure — there are no maintenance doses.

The sirolimus interaction is a practical consideration for the trial. Sirolimus is sometimes co-administered to suppress immune responses to the viral vector. The POLARIS data suggest that in doing so, it may also suppress the therapeutic protein itself. If the top dose level proves durable without sirolimus, that could simplify the treatment protocol and amplify the efficacy signal simultaneously.

What It Means for Patients

Dravet syndrome is a rare but devastating pediatric epilepsy. Standard antiseizure medications — including stiripentol, which enhances GABA neurotransmission, and fenfluramine, reintroduced in the United States and European Union in 2020 specifically for Dravet — reduce seizure burden in some patients but do not stop the progressive neurodevelopmental decline that defines the condition. Families manage an exhausting chronic regimen of multiple daily drugs with limited ceiling on efficacy.

The POLARIS patient eligibility window — six months to seven years — encompasses the period when the developing brain is most vulnerable and most plastic. A therapy that shows the strongest neurodevelopmental gains in children treated before age two suggests a window of opportunity where intervening early may prevent some of the downstream cognitive and behavioral consequences of repeated severe seizures.

Mary Anne Meskis, CEO of the Dravet Syndrome Foundation, put the stakes plainly: "Parents of children with Dravet syndrome live with the fear of every seizure and the heartbreak of watching development stall. To see the early and robust seizure reductions paired with meaningful developmental gains is profoundly encouraging. Families have been waiting for therapies that don't just manage symptoms but give their children a chance to keep learning and growing."

That distinction — between symptom management and genuine disease modification — is what makes the POLARIS dataset consequential. A 76 percent median seizure reduction is clinically meaningful on its own. Paired with Vineland gains and a diverging developmental trajectory, it suggests ETX101 may be addressing the underlying pathophysiology rather than layering another suppressive agent on top of it.

Competitive Landscape

ETX101 enters a field where no gene therapy has yet reached approval for Dravet syndrome, but the competitive pipeline is active. Two organizations frame the landscape at publication time:

Encoded Therapeutics (developer of ETX101) — a clinical-stage biotech with FDA Breakthrough Therapy Designation for ETX101 in Dravet syndrome, the regulatory fast-track status granted to therapies that show preliminary clinical evidence of substantial improvement over available therapy. That designation accelerates FDA interaction and can shorten the review timeline for a future application.
Dravet Syndrome Foundation — maintains an active treatment pipeline tracker covering current clinical trials across gene-based, RNA-based, and small-molecule approaches. Its tracker positions ETX101 within a broader wave of SCN1A-targeted research, suggesting several programs are in earlier preclinical or Phase I stages without yet reporting comparable efficacy data.

A April 2026 review in CNS Drugs catalogued newly approved and investigational RNA and gene-based therapies for Dravet syndrome, confirming that ETX101 sits within an emerging competitive class — not an uncontested space. However, no rival program has reported a 52-week seizure reduction figure comparable to 76 percent at any dose level in peer-reviewed or conference data available at publication time. The single-dose ICV administration model also distinguishes ETX101 from chronic oral regimens, a practically significant differentiator for families managing daily polypharmacy.

Independent analyst commentary specifically on this announcement was not publicly available at publication time.

The Road to Clinic

POLARIS is a multi-site, international Phase I/II trial structured around dose escalation. The program has evaluated at least three dose levels, with early data from a top dose level presented at the 2026 ASGCT Annual Meeting. The Presidential Symposium is one of the conference's highest-profile venues, reserved for late-breaking or landmark data — the choice of disclosure venue signals that Encoded Therapeutics and ASGCT reviewers regarded the dataset as significant.

The ICV administration route shapes the clinical experience. Unlike an intravenous infusion, ICV delivery requires a neurosurgical procedure to access the ventricular system. That procedural complexity is a real consideration for patient and caregiver decision-making, particularly in infants. However, the one-time nature of the administration — no maintenance dosing, no refills, no daily adherence burden — represents a structural advantage over chronic antiseizure regimens.

The POLARIS data package as presented reflects interim findings. Not all enrolled patients have reached all follow-up milestones, and the total enrolled patient count was not disclosed in available data at publication. Safety and adverse event profiles were not detailed in the publicly available ASGCT presentation summary.

What's Next

The immediate signal to watch is the top dose level cohort. The sirolimus interaction data suggest that patients at the highest dose who avoided sirolimus showed the strongest responses, consistent with preclinical models. If that pattern holds as the top dose cohort matures, Encoded Therapeutics will likely need to decide whether to amend the trial protocol to exclude or minimize sirolimus co-administration.

The 52-week durability data at dose level 3 are encouraging, but regulators will require longer-term follow-up before a pivotal trial or biologics license application can proceed. A Phase III trial design will need to specify primary endpoints, control arms — a genuinely difficult design challenge in a rare pediatric disease — and safety monitoring criteria that satisfy both FDA and international regulatory bodies.

The FDA Breakthrough Therapy Designation gives Encoded Therapeutics more frequent and substantive FDA guidance meetings, which can accelerate trial design decisions. The developmental trajectory data, if they hold at longer follow-up, could also support arguments for broader label language beyond seizure reduction alone — a regulatory and commercial consideration that distinguishes disease-modifying candidates from symptomatic treatments.

The company has not publicly disclosed a timeline for Phase III initiation or a biologics license application submission window.

For parents of infants newly diagnosed with Dravet syndrome, the POLARIS data represent the most specific near-term benchmark available: if ETX101 moves toward a pivotal trial with an eligibility window starting at six months, a family receiving an SCN1A diagnosis today would need to act on information about trial enrollment within months, not years. The before-age-two subgroup signal makes the timing question urgent in a way that few other disease contexts produce.

The most clarifying thing about the POLARIS dataset is what it measures that prior Dravet studies did not: not just whether seizures go down, but whether children grow up differently. A 76 percent seizure reduction from a single injection is striking enough. The developmental trajectory data, if they hold through longer follow-up, would represent a qualitative shift in what gene therapy can credibly promise for a pediatric neurological disease. The sirolimus finding adds a layer of optimism most trial reports don't include: the signal may be getting better, not plateauing.

-- Imani Brooks, Consumer Advocacy Editor

Sources: Encoded Therapeutics / Business Wire · GEN Biotechnology · ClinicalTrials.gov — POLARIS